At the annual meeting of the American Association of Cancer Researchers, presenters discuss strategies to improve the safety and effectiveness of reengineered T cells in eradicating tumors.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
|
Krishan Maggon 's curator insight,
February 21, 2015 12:43 PM
Published OnlineFirst February 18, 2015; doi: 10.1158/1078-0432.CCR-14-2085
Tumor Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanomaling Zhang1, Richard A. Morgan1, Joal D Beane2, zhili zheng3, Mark E Dudley4,Sadik H. Kassim1, Azam V Nahvi1, Lien T Ngo1, Richard M. Sherry5, Giao Q Phan1,Marybeth S. Hughes6, Udai S. Kammula6, Steven A. Feldman1, Mary Ann Toomey1,Sid P Kerkar7, Nicholas P. Restifo8, James C. Yang9, and Steven A. Rosenberg10,* +Author Affiliations 1Surgery ranch, Center for Cancer Research, National Cancer Institute,National Institutes of Health2Surgery Branch, Center for Cancer Research, National Cancer Institute,National Institutes of Health3Surgery Branch/NCI, National Cancer Institute4Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health5Surgery Branch, National Cancer Institute, NIH6Surgery Branch, National Cancer Institute7Laboratory of Pathology, National Institutes of Health8Surgery Branch, Center for Cancer Research, National Institutes of Health, National Cancer Institute9National Cancer Institute, Surgery Branch, NCI10Surgery Branch, Center for Cancer Research, National Cancer Institute↵* Corresponding Author:Steven A. Rosenberg, Surgery Branch, Center for Cancer Research, National Cancer Institute, Bldg 10-CRC, Rm 3W-3940, 10 Center Dr, MSC 1201, Bethesda, 20892, United States sar@mail.nih.gov |
CAR T Cell immunotherapy, TIL, ATC, TCR unpredictable toxicity at AACR 2015